📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Imvax

1.1 - Company Overview

Imvax Logo

Imvax

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of patient-specific vaccines and immunotherapies for solid tumors, including IGV-001, a personalized treatment for glioblastoma in Phase 2b trials, and preclinical programs IEC-001 (endometrial), IHC-001 (hepatocellular), IUC-001 (urothelial), and IOC-001 (ovarian). Offers the Goldspire platform to capture a tumor’s full antigen signature for developing personalized immunotherapies.

Products and services

  • IGV-001: Patient-specific, Phase 2b-stage immunotherapy for glioblastoma that stimulates the immune system against the tumor, engineered to deliver personalized anti-tumor activation
  • Goldspire Platform: Platform-technology, solid-tumor-focused system that captures a tumor’s full antigen signature to architect personalized immunotherapies targeting solid tumors
  • IEC-001: Preclinical-stage treatment under development for endometrial cancer, created to address this indication with studies progressing prior to clinical evaluation

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Imvax

Azanta Logo

Azanta

HQ: Denmark Website
  • Description: Provider of pharmaceutical marketing and distribution services, offering a portfolio that includes Amnisure, Cicatridina, Repadina Plus, Cystistat, Flexi-T, Methadone, Oxandrin, Suplasyn, and development products.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Azanta company profile →
AroCell Logo

AroCell

HQ: Sweden Website
  • Description: Provider of biomarker-based diagnostic tests for cancer prognosis, monitoring, and follow-up, including the TK 210 ELISA measuring TK1 as a marker of increased cell turnover. Offers Oncology Diagnostics tools to capture critical clinical data for cancer patient management, and TUBEX TF, a rapid, sensitive in vitro test for detecting acute typhoid fever caused by Salmonella enterica.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full AroCell company profile →
Aprea Therapeutics Logo

Aprea Therapeutics

HQ: Sweden Website
  • Description: Provider of oncology therapeutics focused on discovering and developing anticancer compounds that reactivate the tumor suppressor protein p53, including APR-246, a first-in-class small molecule drug candidate in clinical development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aprea Therapeutics company profile →
Beacon Biomedical Logo

Beacon Biomedical

HQ: United States Website
  • Description: Provider of easy, accurate, and affordable blood-based tests for earlier cancer detection, developing and commercializing waived test (LDT) solutions for healthcare practitioners and individuals. Offerings include BeScreened-CRC, a blood-based colorectal cancer screening test for adults 45+ who are unwilling or unable to undergo traditional screening methods.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Beacon Biomedical company profile →
Oxford Cancer Biomarkers Logo

Oxford Cancer Biomarkers

HQ: United Kingdom Website
  • Description: Provider of colorectal cancer biomarker tests, developing and commercializing a suite of diagnostics to improve the current treatment pathway; closely affiliated with the Institute of Cancer Medicine at Oxford University, where its founders lead translational cancer science research.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Oxford Cancer Biomarkers company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Imvax

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Imvax

2.2 - Growth funds investing in similar companies to Imvax

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Imvax

4.2 - Public trading comparable groups for Imvax

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Imvax

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Imvax

What does Imvax do?

Imvax is a provider of patient-specific vaccines and immunotherapies for solid tumors, including IGV-001, a personalized treatment for glioblastoma in Phase 2b trials, and preclinical programs IEC-001 (endometrial), IHC-001 (hepatocellular), IUC-001 (urothelial), and IOC-001 (ovarian). Offers the Goldspire platform to capture a tumor’s full antigen signature for developing personalized immunotherapies.

Who are Imvax's competitors?

Imvax's competitors and similar companies include Azanta, AroCell, Aprea Therapeutics, Beacon Biomedical, and Oxford Cancer Biomarkers.

Where is Imvax headquartered?

Imvax is headquartered in United States.

How many employees does Imvax have?

Imvax has 1,000 employees 🔒.

When was Imvax founded?

Imvax was founded in 2010 🔒.

What sector and industry vertical is Imvax in?

Imvax is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Imvax

Who are the top strategic acquirers in Imvax's sector and industry

Top strategic M&A buyers and acquirers in Imvax's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Imvax?

Top strategic M&A buyers groups and sectors for Imvax include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Imvax's sector and industry vertical

Which are the top PE firms investing in Imvax's sector and industry vertical?

Top PE firms investing in Imvax's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Imvax's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Imvax's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Imvax's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Imvax include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Imvax's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Imvax?

The key public trading comparables and valuation benchmarks for Imvax include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Imvax for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Imvax with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Imvax's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Imvax with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Imvax's' sector and industry vertical?

Access recent funding rounds and capital raises in Imvax's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Imvax